The HER2-positive breast cancer treatment paradigm has undergone considerable change in recent years and is expected to evolve further as more novel therapies enter the market. The enthusiastic adoption of HER2-targeting biologics, Roche/Genentech’s Perjeta (pertuzumab) and Kadcyla (T-DM1), has increased the barrier of entry for new emerging therapies. However, unmet need still exists for the treatment of advanced/metastatic HER2-positive breast cancer. Our content examines the key drivers of prescribing and analyzes the areas of significant commercial opportunities.

Questions Answered:

  • What are the treatment drivers and goals for advanced/metastatic HER2-positive breast cancer?
  • What attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key treatment drivers and goals for advanced/metastatic HER2-positive breast cancer?
  • What are the prevailing areas of unmet need and opportunity in advanced/metastatic HER2-positive breast cancer?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European medical oncologists for a hypothetical new, advanced/metastatic HER2-positive breast cancer drug?

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 31 European medical oncologists fielded in February 2017.

Key companies: Roche/Genentech, Novartis

Key drugs: Perjeta, Kadcyla, Tykerb/Tyverb

Table of contents

  • Detailed, Expanded Analysis (US & EU): Advanced/Metastatic HER2-Positive Breast Cancer
    • Key Updates
      • December 2017
      • September 2017
      • May 2017
    • Treatment Drivers and Goals
      • Overview
      • Treatment Drivers and Goals
        • Physician Weighting of Clinical and Nonclinical Attributes
        • Methodology
      • Rationale for Treatment Drivers and Goals Selection
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
      • Physician Rating of Treatment Drivers and Goals in Advanced/Metastatic HER2-Positive Breast Cancer
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
        • Nonclinical Factors
      • Stated vs. Derived Importance of Treatment Drivers and Goals
    • Product Performance Against Treatment Drivers and Goals
      • Overview
      • Rationale for Drug Selection
      • Current Brand Performance on Key Treatment Drivers and Goals
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
    • Assessment of Unmet Need
      • Overview
      • Overall Satisfaction with Current Treatment
      • Physician Rating of Unmet Need in Advanced/Metastatic HER2-Positive Breast Cancer
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
      • Unmet Need in Advanced/Metastatic HER2-Positive Breast Cancer and Related Indications
    • Opportunity Analysis
      • Areas of Opportunity in the Advanced/Metastatic HER2-Positive Breast Cancer Market and Emerging Therapy Insights
        • Opportunity: A New Therapy with Improved Efficacy Attributes
        • Opportunity: A New Agent with a Lower Incidence of Hematological and Gastrointestinal Toxicities
        • Opportunity: A New HER2-Targeting Agent with Reduced Cardiotoxicity
        • Opportunity: New Therapies with More-Convenient Routes of Administration
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
      • Attribute Importance and Part-Worth Utilities
        • Advanced/Metastatic HER2-Positive Breast Cancer Target Product Profile: Attribute-Level Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Scenario 1
        • Scenario 2
        • Scenario 3
    • Appendix
      • Experts Interviewed
      • Bibliography

Author(s): Amy Yip, PhD

Amy Yip, is a Business Insights Analyst in the oncology team at Decision Resources Group. Prior to joining DRG, Dr. Yip worked as an analyst at GlobalData where she worked on a number of disease reports within Healthcare and Pharmaceuticals, with a particular focus on oncology. Dr. Yip obtained her doctorate in molecular medicine at the Liggins Institute, University of Auckland, where she investigated the impact of aberrant neurotrophic factor expression on hormone signaling pathways in breast cancer cells. Dr. Yip also holds a BSc (Hons) degree, with first class honors in biomedical science, awarded by the University of Auckland, and has previously worked with Novartis in their New Zealand office.


Related Reports

Breast Cancer | Landscape & Forecast | Disease Landscape & Forecast

Characterized by high incidence and long treatment durations, the breast cancer market represents a great commercial opportunity for drug developers. CDK4

View Details

Breast Cancer | Unmet Need | Detailed, Expanded Analysis: Advanced/Metastatic Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is a patient population with high unmet need given the poor outcomes associated with current treatment...

View Details

Breast Cancer | Access & Reimbursement | Detailed, Expanded Analysis - Optimizing Market Access Amid an Evolving Landscape for HR+/HER2- Therapies (EU)

MARKET OUTLOOK The lucrative HR-positive, HER2-negative breast cancer market in Europe is fast-moving and competitive. CDK4/6 inhibitors Ibrance (Pfizer), Kisqali (Novar...

View Details

Breast Cancer | Epidemiology | Extrapolated Worldwide Coverage

DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key breast cancer patient popu...

View Details